Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
The trans-isomer of clomiphene citrate, a selective estrogen receptor modulator (SERM). Unlike the mixed isomer clomifene (Clomid), enclomiphene is the active anti-estrogenic component without the estrogenic zuclomiphene isomer. Studied as a treatment for secondary hypogonadism that preserves fertility, unlike exogenous testosterone.
A synthetic form of the naturally occurring gonadotropin-releasing hormone (GnRH). Used clinically to evaluate pituitary function and increasingly prescribed in peptide therapy to maintain endogenous testosterone production during TRT or peptide cycles. Acts on the pituitary to stimulate LH and FSH release.
Blocks estrogen receptors in the hypothalamus, removing negative feedback on GnRH release. This increases pulsatile GnRH secretion, which stimulates pituitary LH and FSH production, driving endogenous testosterone synthesis while maintaining spermatogenesis.
Binds to GnRH receptors on gonadotroph cells in the anterior pituitary, triggering pulsatile release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This maintains the HPG axis feedback loop and preserves testicular function, including spermatogenesis.
- Secondary hypogonadism treatment
- Testosterone optimization without TRT
- Post-cycle therapy (PCT)
- Fertility preservation in hypogonadal men
- Alternative to clomiphene with fewer estrogenic side effects
- Maintaining fertility during TRT
- Pituitary function testing
- Hypothalamic amenorrhea treatment
- Post-cycle therapy (PCT)
- Preserving testicular size during hormone therapy
- Headache
- Nausea
- Hot flashes
- Visual disturbances (less common than with clomiphene)
- Not FDA-approved — regulatory status uncertain
- Injection site reactions
- Headache and nausea
- Flushing
- Potential for desensitization with continuous (non-pulsatile) use
- Allergic reactions (rare)
Not FDA-approved. Repros Therapeutics (now Allergan) submitted NDA for Androxal but received a Complete Response Letter in 2015. Currently available through compounding pharmacies. Active interest from telehealth clinics as a TRT alternative.
FDA-approved as Factrel for diagnostic evaluation of pituitary gonadotroph function. Lutrelef (pulsatile gonadorelin) approved in 2024 for hypothalamic amenorrhea. Widely compounded for off-label use in fertility preservation during TRT.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.